Literature DB >> 10440458

Weight gain: side effect of atypical neuroleptics?

T Wetterling1, H E Müssigbrodt.   

Abstract

During clinical experience with the "atypical" neuroleptic drugs clozapine, risperidone, and zotepine, some patients have shown a marked weight gain. To prove whether weight gain is a relevant side effect of atypical neuroleptics, the charts of all patients admitted with DSM-III-R diagnoses of schizophrenia, schizoaffective disorder, or delusional disorder in the years 1991 to 1995 were evaluated. A retrospective chart review was performed, which included all patients who were treated longer than 2 weeks with a single neuroleptic. The data analysis showed that weight gain must be considered as a common side effect of atypical neuroleptics (clozapine, risperidone, sulpiride, or zotepine). The mean weight gain (3.1, 1.5, 1.9, or 4.3 kg, respectively) was significantly higher than that of patients treated with "classic" neuroleptics (mean, 0.0-0.5 kg) (Kruskal-Wallis, p = 0.01). Young and not obese patients show the highest weight increase. Because weight gain occurs in the first weeks of treatment, particularly in previously untreated subjects, this side effect has to be considered in view of compliance with long-term neuroleptic medication.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10440458     DOI: 10.1097/00004714-199908000-00006

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  19 in total

Review 1.  Gene expression profiling with DNA microarrays: advancing our understanding of psychiatric disorders.

Authors:  Julie Pongrac; Frank A Middleton; David A Lewis; Pat Levitt; Károly Mirnics
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

Review 2.  Management of antipsychotic-related weight gain.

Authors:  Lawrence Maayan; Christoph U Correll
Journal:  Expert Rev Neurother       Date:  2010-07       Impact factor: 4.618

3.  Loxapine for Reversal of Antipsychotic-Induced Metabolic Disturbances: A Chart Review.

Authors:  Seema Jain; Rebecca Andridge; Jessica A Hellings
Journal:  J Autism Dev Disord       Date:  2016-04

4.  Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats.

Authors:  Mikhail Kalinichev; Claire Rourke; Alex J Daniels; Mary K Grizzle; Christy S Britt; Diane M Ignar; Declan N C Jones
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

Review 5.  [Differences between men and women in side effects of second-generation antipsychotics].

Authors:  W Aichhorn; A B Whitworth; E M Weiss; H Hinterhuber; J Marksteiner
Journal:  Nervenarzt       Date:  2007-01       Impact factor: 1.214

Review 6.  Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?

Authors:  Wolfgang Aichhorn; Alexandra B Whitworth; Elisabeth M Weiss; Josef Marksteiner
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 7.  Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

Authors:  John W Newcomer
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 8.  Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism.

Authors:  Karen L Teff; Sangwon F Kim
Journal:  Physiol Behav       Date:  2011-06-12

Review 9.  Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review.

Authors:  William A Hargreaves; P Joseph Gibson; Joseph P Gibson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

10.  Bayesian Meta-analysis of Multiple Continuous Treatments with Individual Participant-Level Data: An Application to Antipsychotic Drugs.

Authors:  Jacob Spertus; Marcela Horvitz-Lennon; Sharon-Lise T Normand
Journal:  Med Decis Making       Date:  2019-08-02       Impact factor: 2.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.